0
0
India’s medical technology (MedTech) sector is currently undergoing a transformative phase, aiming to reduce its high dependence on imports while increasing its share in the global market. According to a recent report jointly released by the Confederation of Indian Industry (CII) and Boston Consulting Group (BCG), this sector—valued at approximately $16 billion—represents just around 2% of the global MedTech market estimated at $680 billion. Yet, under the government’s ambitious Viksit Bharat 2047 vision, the sector is earmarked as a strategic pillar of the Make in India agenda with goals to lower import reliance below 50% and grow India’s share of the global MedTech market to 10-12% over the next 25 years.
Key Findings and Developments
The CII-BCG report highlighted several critical achievements and strategic initiatives shaping this vision. India has made significant strides in building medical device manufacturing capacity through the establishment of four dedicated MedTech parks, with the Andhra Pradesh MedTech Zone (AMTZ) standing out as the most advanced facility. Alongside infrastructure development, government-led financial incentives such as the Production-Linked Incentive (PLI) scheme and state-level tax benefits have further fueled growth. These measures are complemented by an enhanced R&D ecosystem supported by government grants and foreign direct investment—attracting approximately USD 3.9 billion by the end of 2024—and upskilling programs led by institutions like the National Institute of Pharmaceutical Education and Research (NIPER).
Import reliance, which was around 80% in fiscal year 2022, has decreased to approximately 60% by 2024 due to these combined efforts. The report also underscores India’s rising private investment from both domestic and multinational corporations, which is critical to sustaining this momentum.
Expert Perspectives
Dr. Amit Agrawal, Secretary of the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, emphasized the sector’s transformative opportunity, describing India’s MedTech industry as poised to become a global manufacturing and innovation hub. Vishal Goel, Managing Director of Rx Propellant, acknowledged the ongoing reliance on imported advanced medical devices but also highlighted the growth of Indian MedTech exports, suggesting a nuanced transition phase where global suppliers bridge technology gaps while domestic innovation accelerates.
Context and Background
India ranks among the top 20 global medical devices markets and is the fourth-largest in Asia. The domestic market has grown rapidly at 15% annually over the past three years, with projections estimating an increase to $30 billion by 2030. Importantly, India produces a range of devices including in vitro diagnostics, orthopedic implants, ophthalmic devices, and self-care technologies, manufactured across a network of roughly 800 companies.
However, the report recognizes several systemic challenges that could impede reaching ambitious targets. These include ecosystem gaps in high-end medical device manufacturing, regulatory complexities, shortages of skilled manpower, under-utilization of MedTech parks, and limited participation of micro, small, and medium enterprises (MSMEs) in incentive schemes. Addressing these challenges is vital for accelerating growth and competitiveness.
Implications for Public Health
Reducing import reliance on critical medical technologies directly impacts the accessibility, affordability, and quality of healthcare in India. The domestic manufacturing of advanced equipment can lower costs and improve supply chain resilience, particularly important for high-value devices like MRI scanners or surgical robotic systems, currently heavily imported. Broader availability of such equipment enhances diagnostic and therapeutic options, which is crucial amid India’s ongoing dual burden of communicable and non-communicable diseases.
Furthermore, expanding the MedTech industry supports economic growth, job creation, and skill development, aligning with national goals of self-reliance and health system strengthening. The sector’s growth also positions India as a trusted global hub, potentially benefiting international healthcare markets with affordable, high-quality medical devices.
Limitations and Counterarguments
Despite the optimism, some experts caution that the pace of reducing import dependency, especially for high-end and cutting-edge technologies, remains challenging. The availability of skilled professionals and the regulatory framework require substantial strengthening to match global standards. Additionally, the under-utilization of existing MedTech parks and constrained participation of smaller enterprises could limit scalability without targeted government intervention.
Balanced Reporting
The report and expert insights collectively emphasize a balanced view—acknowledging significant progress while realistically addressing hurdles. It calls for fine-tuning policy measures such as the PLI scheme to better include MSMEs, rationalizing import duties, developing a raw material ecosystem, encouraging multinational corporations to expand manufacturing and R&D in India, and increasing collaboration between government, industry, and academia to foster innovation.
Practical Takeaways for Readers
For healthcare professionals and consumers alike, the growing MedTech sector signals potential improvements in the availability of domestically produced medical technologies that could reduce costs and improve care access over time. The sector’s development highlights the interplay between health policy, industrial growth, and patient benefit, illustrating how strategic economic initiatives can drive better healthcare outcomes. Consumers may increasingly encounter high-quality Indian-made medical devices in care settings, while providers can expect a broader range of locally available technologies.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
